Dr. Liu on ADCs Under Exploration in NSCLC
Stephen V. Liu, MD, discusses the expanding exploration of antibody-drug conjugates in non–small cell lung cancer.
Advanced NSCLC: The Advent of Frontline IO Monotherapy
Focusing on single-agent immunotherapy in advanced NSCLC, experts review key data from the KEYNOTE-024, IMpower110, and EMPOWER-Lung 1 clinical trials.
Paradigm for Immunotherapy in Advanced Non-Small Cell Lung Cancer
Expert oncologists review the current state of molecular testing and PD-L1 expression in the setting of advanced non–small cell lung cancer management.
Second-Line Treatment of SCLC
Vamsidhar Velcheti, MD, leads the discussion on the current standard of care and approaching the treatment of second-line SCLC.
Updated Results of the CASPIAN Trial in SCLC From ESMO 2021
John V. Heymach, MD, PhD, reviews updated results from the phase III CASPIAN trial for patients with extensive-stage SCLC (small cell lung cancer) as presented at ESMO 2021.
Immunotherapies in the Treatment of Extensive-Stage SCLC
Sandip P. Patel, MD, reviews results and clinical implications from the CASPIAN study, and Heather Wakelee, MD, shares insight on approaching the optimal immunotherapy option for patients with extensive-stage SCLC.
IMpower133 Trial for Extensive-Stage SCLC
Stephen Liu, MD, reviews outcomes from the IMpower133 trial and comments on the current standard of care for the first-line treatment of extensive-stage SCLC.
Treatment Options for Limited-Stage SCLC
John V. Heymach, MD, PhD, provides an overview of small cell lung cancer (SCLC), and Ani Balmanoukian, MD, reviews available treatment options for limited-stage disease.
Treatment of Advanced NSCLC Following Progression on Immunotherapy
Lung cancer experts provide insight on updates from key clinical trials presented at ESMO 2021 on PD-1 inhibitor–resistant NSCLC.
Role of Immunotherapy in Early Stage NSCLC Treatment
Dr Heather Wakelee reviews results from the IMpower110 study for first-line metastatic NSCLC treatment.
Updates From CheckMate 9LA and POSEIDON Studies in Advanced NSCLC
Heather Wakelee, MD, shares updates from the CheckMate 9LA study, and Vamsidhar Velcheti, MD, reviews key data from the phase 3 POSEIDON study for patients with NSCLC.
Chemoimmunotherapy in Advanced NSCLC Treatment
Experts in lung cancer discuss recent updates from ESMO 2021 and IASLC 2021 WCLC on combination immunotherapy plus chemotherapy for the treatment of advanced NSCLC.
Treatment of Advanced NSCLC With Dual Immune Checkpoint Inhibitors: 4-Year Update of CheckMate 227
Sandip P. Patel, MD, reviews updates on dual immunotherapy agents for the treatment of advanced NSCLC including the 4-year update from the CheckMate 227 study.
Treatment of Advanced NSCLC With Immune Checkpoint Inhibitors
Drs Vamsidhar Velcheti, Ani Balmanoukian, Heather Wakelee, and Stephen Liu discuss recent updates on single-agent immunotherapy regimens in patients with NSCLC.
Treating ALK-Mutant and KRAS G12C–Mutant NSCLC
Lung cancer experts share updates in the treatment of ALK-mutant NSCLC and KRAS G12C–mutant NSCLC as seen in the CROWN study, BrigALK2 real-world study, and CODEBreaK 100 study.
Treatment of MET Exon 14 Mutations in NSCLC
Heather Wakelee, MD, reviews key data for the treatment of MET exon 14 mutations in NSCLC as seen in the GeoMETry-III trial and the CRYSALIS study.
Treating EGFR Exon 20 Insertions and HER2-Mutant NSCLC
Dr Vamsidhar Velcheti evaluates the use of mobocertinib in patients with EGFR exon 20 insertions, and Drs John V. Heymach and Sandip P. Patel discuss the treatment of HER2-mutant NSCLC.
Treatment of TKI-Refractory EGFR-Mutant NSCLC
Heather Wakelee, MD, and Stephen Liu, MD, review the treatment of TKI-refractory EGFR-mutant NSCLC.
Recent Updates in EGFR-Mutant NSCLC Treatment Landscape
Experts in lung cancer provide insight on recent updates from the ESMO Congress 2021 for the treatment of EGFR-mutant NSCLC.
Sequencing Treatments in EGFR-Mutant NSCLC
Vamsidhar Velcheti, MD, and Stephen Liu, MD, discuss their treatment approaches for patients with EGFR-mutant NSCLC who progress on osimertinib.
Black Women With HR+ Breast Cancer Have Worse Outcomes, Despite Similar Recurrence Scores
Benefit of Adjuvant Abemaciclib Increases at 4-Year monarchE Landmark Analysis for Patients With HR+/HER2– High-Risk Early Breast Cancer
Everolimus Plus Adjuvant Endocrine Therapy Fails to Improve iDFS, OS in HR+/HER2- Breast Cancer
Frontline Ribociclib Plus Endocrine Therapy Provides PFS Benefit in Pre/Perimenopausal HR+/HER2- Advanced Breast Cancer
2 Clarke DriveSuite 100Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.